Read more
15:41 · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

Biogen
Shares
BIIB.US, Biogen Inc
-
-

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

3 November 2025, 15:26

US focus: three things to watch this week

3 November 2025, 07:23

The Week Ahead

31 October 2025, 19:08

Daily summary: Sentiments on Wall Street stall at the end of the week🗽US Dollar gains

31 October 2025, 16:08

AbbVie near 1-month low after earnings report 📉

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 2 Million investors from around the world